Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Applied Molecular Transport Inc.
Headquarters: South San Francisco, CA, United States of America
Website: N/A
Year Founded: 2011
Status: Acquired
BioCentury | Aug 14, 2023
Management Tracks
Gardner named CEO of Flagship’s Ampersand
Plus: Brian Powl joins Kura as CCO, and updates from BioNTech, Allogene, CG and more
BioCentury | Jul 28, 2022
Management Tracks
Liz Bhatt becomes COO at Septerna
Plus new CBO, chief HR officer and head of regulatory at Prime, and SVP hires at CBM
BioCentury | Jul 7, 2022
Regulation
July 6 Quick Takes: FDA authorizes pharmacists to prescribe Paxlovid
Plus January PDUFA date for Biogen, Eisai Alzheimer’s therapy, and updates from Genentech, Sarepta, CytomX and more
BioCentury | Mar 14, 2022
Management Tracks
Camp4 hires Barbier as CMO, Sandrock joins SAB
Plus Panagos becomes IQVia’s president of R&D solutions, updates from Curie and Applied Molecular Transport
BioCentury | Jul 2, 2021
Distillery Therapeutics
Adding an IL-10 fusion protein to T cell therapy or immune checkpoint blockade in solid tumors
DISEASE CATEGORY: Cancer
INDICATION: Colorectal cancer; melanoma A recombinant IL-10 fusion protein could enhance the efficacy of adoptive T cell transfer and immune checkpoint blockade in solid
INDICATION: Colorectal cancer; melanoma A recombinant IL-10 fusion protein could enhance the efficacy of adoptive T cell transfer and immune checkpoint blockade in solid
BioCentury | Jan 20, 2021
Management Tracks
Marincola to lead Kite’s cell therapy research; plus moves at T-knife, Applied Molecular Transport, Frequency and NexImmune
Kite Pharma Inc. hired Francesco Marincola as SVP and global head of cell therapy research, effective Feb. 1. Marincola joined the Gilead Sciences Inc. (NASDAQ:GILD) unit from Refuge
BioCentury | Jun 9, 2020
Finance
Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings
BioCentury | Jun 6, 2020
Finance
Legend’s $424M NASDAQ offering pads 2020’s lead over prior years
This year’s IPO tally stands at $6.2B, ahead of the past two years thanks to larger deals
BioCentury | Jun 3, 2020
Finance
Third Rock-launched Pliant is latest biotech to climb on public debut
Three more biotechs hope to price deals on NASDAQ this week
Items per page:
1 - 10 of 14